TBPH Stock Price, Chart, Stats & News

Theravance Biopharma, Inc.
Save
861.45M
Market cap
7.49x
Current P/E
7.63x
Forward P/E
TBPH chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 94.87% |
Operating margin | -12.33% |
Pretax margin | 120.27% |
Net margin | 98.54% |
Effective tax rate | 18.07% |
ROA | 21.81% |
ROE | 46.03% |
D/E | 0.25x |
Interest coverage ratio | -5.38x |
TBPH valuation
P/E | 7.49x |
P/S | 7.23x |
P/B | 2.59x |
P/CF | 3.22x |
P/FCF | 3.26x |
P/OCF | 3.22x |
PEG | 0.03x |
EV multiple | 1050.57x |
About
Theravance Biopharma, Inc. is a biopharmaceutical firm focused on discovering, developing, and bringing to market treatments for respiratory conditions across North America, Europe, and Asia. Its portfolio features YUPELRI, a daily, nebulized long-acting muscarinic antagonist (LAMA) prescribed for chronic obstructive pulmonary disease (COPD). The company also maintains a substantial pipeline of experimental medications.
Similar securities
Based on sector and market capitalization
Report issue











